PMI affiliate and first-year assistant professor in the Department of Neuroscience, Dr. Summer Thyme, is UAB’s first recipient of a prestigious Klingenstein-Simons Fellowship! Dr. Thyme’s work focuses investigating pathways regulated by genes associated with psychiatric disorders (epilepsy, schizophrenia, and autism). This award will support Summer’s work to establish new approaches in drug discovery and precision medicine associated with neuropsychiatric disease, specifically rare genetic mutations that have a clear role in illness.
A UAB team, lead by PMI’s Associate Director, Nita Limdi, PhD has been selected as a new enhanced diversity clinical site to better understand how to employ genomic risk assessments, especially in minority populations, in managing common chronic conditions. For more information see the NHGRI press release.
Since February, we have pivoted our focus towards finding therapeutics to treat and prevent COVID19. One category of therapeutics we identified early on were anti-androgenic compounds, which have been shown to down regulate TMPRSS2, a key host protease important in viral infection. Degarelix falls into this anti-androgenic class of therapeutics, and has been previously FDA-approved as a hormonal regulator to treat prostate cancer. Our recommendation of Degarelix to The U.S. Department of Veterans Affairs has led to the development of clinical trials at multiple hospitals across the nation.
Aleksandra Foksinska, a PMI analyst, successfully completed het undergraduate thesis titled: “From genetic variant to treatment: the role of an analyst in precision medicine”. We are very proud of Aleksandra and appreciate all her hard work.